Fidelity Investments
CAPR icon

Fidelity Investments’s Capricor Therapeutics CAPR Stock Holding History

Fidelity Investments’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.5M Sell
772,649
-149,985
-16% -$4M ﹤0.01% 1722
2025
Q4 		$26.6M Buy
922,634
+898,944
+3,795% +$11.7M ﹤0.01% 1673
2025
Q3 		$171K Sell
23,690
-500
-2% -$3.68K ﹤0.01% 3425
2025
Q2 		$240K Sell
24,190
-566
-2% -$5.98K ﹤0.01% 3241
2025
Q1 		$235K Buy
24,756
+949
+4% +$13.2K ﹤0.01% 3184
2024
Q4 		$329K Sell
23,807
-537
-2% -$9.41K ﹤0.01% 3071
2024
Q3 		$370K Buy
+24,344
New +$120K ﹤0.01% 2982
2024
Q2 		– Sell
-1
Closed -$7 – 5394
2024
Q1 		$7 Buy
+1
New +$5 ﹤0.01% 5286
2021
Q4 		– Sell
-40
Closed – – 4374
2021
Q3 		$0 Hold
40
– – ﹤0.01% 4391
2021
Q2 		$0 Sell
40
-185
-82% -$784 ﹤0.01% 4284
2021
Q1 		$1K Buy
+225
New +$1.3K ﹤0.01% 3805

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments's CAPR Position: Q1 2026 in Review

Fidelity Investments reduced its Capricor Therapeutics (CAPR) stake by 16% in Q1 2026, selling an estimated $4M and leaving 772,649 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

Fidelity Investments first reported a position in CAPR in Q1 2021 and has held it in 11 quarters since. The position peaked at $26.6M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Fidelity Investments held 772,649 shares of Capricor Therapeutics worth $23.5M as of Q1 2026.
  • Fidelity Investments sold 149,985 Capricor Therapeutics shares in Q1 2026, an estimated $4M.
  • Capricor Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1722 holding.
  • Fidelity Investments first reported a position in Capricor Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Fidelity Investments's Capricor Therapeutics position peaked at $26.6M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.